SUPPLEMENTARY DATA

Tabla 1 of the supplementary data

Baseline clinical, angiographic and procedural characteristics in patients in the RIBS IV and V trials included or not in the OCT substudy

	No OCT n = 434 (87%)	OCT n = 64 (13%)	*P*
Age, y	66 ± 10	65 ± 12	.56
Female sex	66 (15)	11 (17)	.68
Risk factors			
Diabetes mellitus	168 (39)	22 (34)	.51
Insulin-dependent	64 (15)	6 (9)	.25
Hyperlipidemia	321 (74)	41 (64)	.10
Hypertension	323 (74)	44 (69)	.34
Eversmoker	259 (60)	43 (67)	.25
Clinical features			.95
Unstable angina	213 (49)	26 (41)	.21
Previous myocardial infarction	222 (51)	41 (64)	.05
Previous bypass surgery	41 (9)	3 (5)	.21
Time to restenosis, d	517 [226-1703] 1169 ± 1362	237 [233-2006] 1143 ± 1327	.55 .28
Ejection fraction, %	58 ± 11	62 ± 13	.01
Target artery			.38
Left anterior descending	192 (44)	28 (44)	
Left circumflex	88 (20)	16 (25)	
Right coronary	137 (32)	20 (31)	
Graft	17 (4)	0 (0)	

Previous ST type			.45
BMS	162 (37)	27 (42)	
DES	272 (63)	37 (58)	
Length previous stent, mm	20 ± 7	20 ± 7	.76
Procedural characteristics			
Treatment strategy			.59
PCB	219 (51)	30 (47)	
EES	215 (50)	34 (53)	
Length new EES/PCB, mm	20 ± 8	21 ± 7	.21
Maximal pressure, atm	19 ± 4	20 ± 4	.003
Inflation time, sec (+)	83 ± 51	103 ± 55	.06
	80 [40-105]	100 [60-120]	.02
Maximal balloon	3.13 ± 0.5	2.99 ± 0.4	.01
Balloon-to-artery ratio	1.21 ± 0.2	1.21 ± 0.2	.99
Crossover	14 (3)	0 (0)	.23
Angiographic success	434 (100)	64 (100)	1

BMS, bare metal stent; DES, drug-eluting stent; EES, everolimus eluting stent; OCT, optical coherence tomography; PCB, paclitaxel coated balloon.

The data are expressed as No. (%), mean ± standard deviation, or median [interquartile range].

Table 2 of the supplementary data

Angiographic results in patients in the RIBS IV and V trials included or not in the OCT substudy

	No OCT n = 434 (87%)	OCT n = 64 (13%)	*P*
Mehran I,II,III-IV	232 (54), 162 (37), 40 (9)	36 (56), 22 (34), 6 (9)	.90
B2-C lesion	203 (47)	34 (53)	.34
Edge-ISR	74 (17)	14 (22)	.35
Quantitative findings	(n = 434)	(n = 64)	
Before the procedure			
Reference vessel diameter, mm	2.65 ± 0.5	2.54 ± 0.5	.11
Minimum lumen diameter, mm	0.86 ± 0.4	0.77 ± 0.3	.05
Stenosis (% of lumen diameter)	67 ± 16	69 ± 13	.31
Lesion length, mm	11.6 ± 6	12.9 ± 7	.14
Diffuse lesions, ≥ 10 mm	209 (49)	37 (60)	.11
After the procedure			
Reference vessel diameter, mm	2.62 ± 0.5	2.51 ±0.5	.11
Minimum lumen diameter, mm	2.22 ± 0.5	2.06 ± 0.5	.016
Stenosis (% of lumen diameter)	15 ± 11	17 ± 12	.16
Acute gain, mm	1.36 ± 0.5	1.31 ± 0.5	.47
At follow-up	(n = 380)	(n = 62)	
Reference vessel diameter, mm	2.68 ± 0.6	2.57 ± 0.5	.13
Minimal lumen diameter, mm	2.04 ± 0.7	1.89 ± 0.7	.10
Stenosis (% of lumen diameter)	23 ± 21	26 ± 24	.37
Restenosis	43 (11)	11 (18)	.15
Late loss, mm (mean/median)	0.18 ± 0.7 / 0.06 (−0.19 to 0.41)	0.22 ± 0.6 / 0.07(−0.12 to 0.39)	.69 .86
Loss index (mean/median)	0.08 ± 0.6 / 0.04 (−0.15 to 0.29)	0.17 ± 0.5 / 0.07 (−0.12 to 0.39)	.23 .66

Net gain, mm	1.18 ± 0.7	1.09 ± 0.7	.39

ISR, in stent restenosis; OCT, optical coherence tomography.

The data are expressed as No. (%), mean ± standard deviation or median [interquartile range].